Department of Imaging and Pathology, University Hospitals Leuven-KU Leuven, Leuven, Belgium.
Department of Otorhinolaryngology-Head and Neck Surgery and Department of Oncology, Section Head and Neck Oncology, University Hospitals Leuven-KU Leuven, Leuven, Belgium.
Diagn Cytopathol. 2020 Nov;48(11):972-978. doi: 10.1002/dc.24515. Epub 2020 Jun 7.
Salivary gland fine needle aspiration (FNA) has a well-established role in the evaluation of salivary gland lesions. The Milan system for reporting salivary gland cytopathology (MSRSGC) was developed in 2018 to accomplish a standardized reporting across institutions. This classification is predominantly based on the use of direct smears. This single center study aims to evaluate and further validate the MSRSGC based on the sole use of cell blocks and carry out a risk assessment based on follow up histopathology.
A total of 359 FNA specimens from 343 patients processed as cell blocks between 2012 and 2018 were retrieved, with histologic follow-up available in 235 cases. The cytological diagnosis were reclassified according to the MSRSGC categories: non-diagnostic, non-neoplastic, atypia of undetermined significance (AUS), benign neoplasm, salivary gland neoplasm of uncertain malignant potential (SUMP), suspicious for malignancy (SFM), and malignant. The use of ancillary immunohistochemistry or molecular testing was recorded. The risk of malignancy (ROM) was calculated for each diagnostic category.
Overall accuracy, sensitivity, specificity, positive predictive value, and negative predictive value were 92.9%, 75.9%, 97.9%, 91.7%, and 95%, respectively. The ROM for the non-diagnostic, non-neoplastic, AUS benign neoplasms, SUMP, SFM and malignant categories were 13.8%, 14.2%, 30%, 6.3%, 20.8%, 60%, and 100%, respectively.
This large single center retrospective series further validates the MSRSGC. The proposed diagnostic classification is reproducible with use of cell blocks. Discrepancies in number of cases per category and ROM are based on cross-institution variabilities, pre-FNA diagnostics (imaging) and ancillary tests.
唾液腺细针抽吸(FNA)在评估唾液腺病变方面具有成熟的作用。2018 年制定了米兰唾液腺细胞病理学报告系统(MSRSGC),以实现跨机构的标准化报告。该分类主要基于直接涂片的使用。本单中心研究旨在仅使用细胞块评估和进一步验证 MSRSGC,并根据随访组织病理学进行风险评估。
共检索了 2012 年至 2018 年间作为细胞块处理的 343 例患者的 359 例 FNA 标本,其中 235 例有组织学随访。根据 MSRSGC 类别重新分类细胞学诊断:非诊断性、非肿瘤性、意义未确定的非典型性(AUS)、良性肿瘤、唾液腺低度恶性潜能肿瘤(SUMP)、疑似恶性(SFM)和恶性。记录辅助免疫组织化学或分子检测的使用情况。计算每个诊断类别的恶性肿瘤风险(ROM)。
总体准确率、敏感度、特异度、阳性预测值和阴性预测值分别为 92.9%、75.9%、97.9%、91.7%和 95%。非诊断性、非肿瘤性、AUS 良性肿瘤、SUMP、SFM 和恶性类别的 ROM 分别为 13.8%、14.2%、30%、6.3%、20.8%、60%和 100%。
本大型单中心回顾性系列进一步验证了 MSRSGC。使用细胞块可重现提出的诊断分类。每个类别病例数和 ROM 的差异基于跨机构变异性、预 FNA 诊断(影像学)和辅助检测。